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The aims of this study were to synthesize a series of thiosemicarbazones and their thiazole derivatives, 
to investigate their cytotoxic activity against three human cancers and normal (Vero cells) cell lines, 
and to evaluate the pro-apoptotic potential of the most active compounds. Materials and Methods: The 
thiosemicarbazones were obtained by reacting an aromatic aldehyde with thiosemicarbazide (yield 
71-96%), which were subjected to a cyclization with α-bromoacetophenone to yield the required 
thiazole heterocycles (yield 63-100%). All the synthesized compounds were screened at 50 µM 
concentration against three cell lines representing HL60 (promyelocytic leukemia), Jurkat (acute 
lymphoblastic leukemia), and MCF-7 (breast cancer). The pro-apoptotic effect was measured by flow 
cytometry as the percentage of cells with hypodiploid DNA. Results: Three thiazole compounds showed 
activity against at least one tumor cell line (IC50 = 43-76 µM) and low cytotoxicity against Vero cells  
(IC50 > 100 µM). The most active compound of this series induced 91% and 51% DNA fragmentation in 
HL60 and MCF-7 cell lines, respectively, suggesting that this compound triggered apoptosis in these cells. 
Conclusion: Among the synthesized compounds, one in particular was found to exert antiproliferative 
and pro-apoptotic activity on tumor cells and can be considered promising as a lead molecule for the 
design of new analogues with improved activity.
Uniterms: Thiosemicarbazones/synthesis. Thiosemicarbazones/cytotoxic activity. Thiazoles/derivatives/
synthesis. Thiazoles/derivatives/cytotoxic activity.
O estudo teve como objetivo a síntese de uma série de tiossemicarbazonas e seus derivados tiazólicos e 
a avaliação da atividade citotóxica contra três linhagens de células tumorais humanas e células normais 
(Vero), a fim de se avaliar o potencial pró-apoptótico dos compostos mais ativos. As tiossemicarbazonas 
foram obtidas por reação entre um aldeído aromático e tiossemicarbazida (rend. 71-96%), as quais foram 
submetidas à ciclização com α-bromoacetofenona, fornecendo os heterociclos tiazólicos desejados 
(rend. 63-100%). Todos os compostos sintetizados foram testados na concentração de 50 µM contra três 
linhagens de células tumorais: HL60 (leucemia promielocítica), Jurkat (leucemia linfoblástica aguda) e 
MCF-7 (câncer de mama). O efeito pró-apoptótico foi avaliado por citometria de fluxo como porcentagem 
de células com DNA hipodiplóide. Três compostos tiazólicos foram ativos contra, pelo menos, uma 
linhagem tumoral (CI50=43-76 µM), com baixa citotoxicidade contra células Vero (CI50 > 100 µM). 
O composto mais ativo dessa série induziu fragmentação do DNA de 91% e 51% nas linhagens HL60 
e MCF-7, respectivamente, sugerindo que este composto ativou a apoptose nessas células. Dentre os 
compostos sintetizados, um em particular apresentou atividade antiproliferativa e pró-apoptótica em 
células tumorais e pode ser considerado composto protótipo promissor na busca por novos análogos 
com atividade melhorada.
Unitermos: Tiossemicarbazonas/síntese. Tiossemicarbazonas/atividade citotóxica. Tiazol/derivados/
síntese. Tiazol/derivados/atividade citotóxica.
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INTRODUCTION
Thiosemicarbazones and their thiazole heterocyclic 
derivatives are of great importance in pharmacology 
due to their broad range of biological activities, such as 
anticonvulsant, antimicrobial, and antiparasitic activities 
(Gaikwad, Patil, Bobade, 2013; Souza et al., 2013; Bharti 
et al., 2010; Siddiqui et al., 2009; Oliveira et al., 2008a; 
Souza, 2005; Dimmock et al., 1991). 
The synthesis of thiazole compounds from 
thiosemicarbazones is of particular interest in medicinal 
chemistry due to their ease of synthesis, low cost, good 
yields, and the possibility of obtaining a wide diversity of 
derivatives, allowing the modulation of pharmacokinetics 
and optimization of biological activity. In addition, this 
class of heterocyclic compounds has demonstrated great 
potential as anticancer agents with a broad spectrum of 
action against different types of cancer cell lines (Abdel-
Maksoud et al., 2016; Turan-Zitouni et al., 2016; Morigi 
et al., 2015; Zhao et al., 2015). 
In this context, and following the work developed 
by our research group in the development of new 
compounds with antitumor activity (Lages et al., 2013; 
Soares et al., 2010), the present study aimed to synthesize 
thiosemicarbazones and their thiazole derivatives 
(Figure 1) and to evaluate their antiproliferative activity 
against three human tumor cell lines: HL60 (promyelocytic 
leukemia), Jurkat (acute lymphoblastic leukemia), and 
MCF-7 (breast cancer). The cytotoxic activity against Vero 
cell lines (normal monkey kidney cells) was also aimed to 
investigate the selectivity of the compounds to nontumor 
cells, which have been used as a preliminary model 
to assess the selectivity of new bioactive compounds 
(Lavrado et al., 2010; Küster et al., 2012). 
Apoptosis or programmed cell death is an important 
parameter in drug-induced toxicity (Weber et al., 
2004). Deregulation of apoptosis-regulating genes can 
lead to diseases such as cancer and has been related to 
pathogenesis and cancer progression (Fischer, Schulze-
Osthoff, 2005). Drugs that restore the normal apoptotic 
pathways have the potential for effectively treating cancers 
that depend on aberrations of the apoptotic pathway 
to stay alive (Fesik, 2005). Therefore, the search for 
compounds capable of inducing apoptosis in tumor cells 
is of great interest in the development of novel drugs for 
cancer treatment. In this context, we also evaluated the 
apoptotic potential of the active compounds measuring 
the increase of diploid DNA content of susceptible cells 
by flow cytometry, as a preliminary study to gain insights 
into their action mechanism comparing with etoposide, a 
pro-apoptotic drug used in the clinic.
MATERIAL AND METHODS
General procedures
Melting points were determined on a Microquímica 
MQAPF 301 apparatus and are uncorrected. FT-IR 
spectra were recorded using a Perkin Elmer Spectrum 
One infrared spectrometer and absorptions are reported 
as wave numbers (cm-1). All NMR spectra were recorded 
on a Bruker Avance DPX 200 spectrometer (200 MHz). 
Chemical shifts are given in δ (ppm) scale and J values are 
given in Hz. All reagents of analytical grade were obtained 
from commercial suppliers and used without previous 
purification. Reactions were monitored by TLC using 
silica gel coated plates and different solvents solutions 
as the mobile phase. The synthesis of the compounds 
1a and 1c (Rajak et al., 2011), 1b (Tenório, Carvalho, 
Pessanha, 2005), 1d (Grammaticakis, Sorbonne, 1959), 1e 
(Behnisch, Mietzsch, Schmidt, 1955), 1f (Oliveira et al., 
2008b), 2a and 2c (Shih, Su, Wu, 2007), 2b (Maccioni et 
al., 2003) and 2e (Bilinski, Tyburczyk, Urban, 1961) was 
previously reported in the literature. 
General procedure: synthesis of thiazole heterocycles 
(Dimmock et al., 1991) 
To a solution of 1 equiv. of thiosemicarbazones 
(1a-1f) in isopropyl alcohol was added 1 equiv. 
o f  2 - b r o m o a c e t o p h e n o n e  o r  2 - b r o m o - 4 ’ -
methoxyacetophenone, and the resulting mixture was 
kept under reflux and magnetic stirring (approximately 
90 minutes or indicated time). After cooling to room 
temperature, part of the solvent was removed under 
FIGURE 1 - General structure of synthesized thiosemicarbazones and hetetocycles.
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reduced pressure and the formed precipitate was filtered, 
washed with saturated solution of NaHCO3 followed by 
cold distilled water. 
4-Phenyl-2-(2-(quinolin-4-ylmethylene)hydrazinyl)
thiazole (2d).
 The reaction was carried out following the general 
procedure described above affording 0.141 g of a brownish 
solid (65% yield). Mp 112.0-114.5 ºC. IR, (ῡ/cm–1): 
3452 (NH), 1659 (C=N), 1619, 1594, 1551, 1452 (C=C 
aromatic). 1H NMR (200 MHz, DMSO-d6), δ/ppm: 12.68 
(1 H, s, NH); 8.94 (1 H, d, quinoline); 8.93-8.70 (2 H, m, 
quinoline and CH=N); 8.07 (1 H, d, H-8 quinoline); 7.90-
7.68 (5 H, m, quinoline and ArH); 7.46-7.27 (4 H, m, ArH 
and H-thiazole). 13C NMR (50 MHz, DMSO-d6), δ/ppm: 
167.7 (SC=N); 150.7; 150.2; 148.3 (C-4 thiazole, C-2, 
C-9 quinoline); 138.0 (CH=N); 137.4 (C-4 quinoline); 
134.5 (C-Ph); 129.7, 129.6, 128.6 (C-Ph), 127.7, 127.4, 
125.6 (C-Ph), 124.2 (C-5, C-6, C-7, C-8 quinoline and 




 The reaction was carried out following the general 
procedure described above affording 0.066 g of an orange 
solid (92% yield). Mp 208.3 ºC with decomposition. IR, 
(ῡ/cm–1): 1597 (C=N), 1580, 1562, 1483 (C=C aromatic), 
1508, 1343 (NO2). 1H NMR (200 MHz, DMSO-d6), δ/ppm: 
12.33 (1 H, s, NH); 8.29 (2 H, broad s., ArNO2); 7.98 (3 H, 
broad s., CH=N + ArNO2); 7.85 (2 H, br. s., ArH); 7.42-
7.37 (5 H, m, 2 x ArH, H-thiazole and H-5 furan); 7.00 (1 
H, s, H-2 furan). 13C NMR (50 MHz, DMSO-d6), δ/ppm: 
167.6 (SC=N); 151.6, 151.1, 150.4 (C-4 thiazole, C-2 and 
C-5 furan); 146.1 (C-ArNO2); 135.3, 134.5 (C-ArNO2 and 
C-Ph); 130.7 (CHC=N); 128.6 (C-Ph), 127.6 (C-Ph); 125.9 
(C-Ph); 124.5, 124.2 (C-ArNO2); 114.2 (C-4 furan); 112.6 
(C-3 furan); 103.9 (CH- thiazole).
4-(4-Methoxyphenyl)-2-(2-(3-nitrobenzylidene)
hydrazinyl)thiazole (2g). 
The reaction was carried out following the general 
procedure described above affording 0.168 g of a yellow 
solid (quantitative yield). Mp 190.0-193.3 ºC. IR, (ῡ/
cm–1): 3314 (NH), 1587 (C=N), 1527, 1346 (NO2), 1511, 
1463 (C=C aromatic). 1H NMR (200 MHz, DMSO-d6), 
δ/ppm: 8.45 (1 H, s, ArNO2); 8.20-8.16 (2 H, m, ArNO2 
and HC=N); 8.07 (1 H, d, ArNO2); 7.79-7.67 (3 H, m, 
ArNO2 and ArOCH3); 7.19 (1 H, s, H-thiazole); 6.97 (2 
H, d, ArOCH3); 3.77 (3 H, s, OCH3). 13C NMR (50 MHz, 
DMSO-d6), δ/ppm: 167.9 (SC=N); 159.0 (C-ArOCH3); 
148.3 (C-4 thiazole); 151.5 (C-ArNO2); 139.4 (CH=N); 
136.2 (C-ArNO2); 132.4 (C-ArNO2); 130.4 (C-ArNO2); 
127.0 (C-ArOCH3); 126.9 (C-ArOCH3); 123.4 (C-ArNO2); 




 The reaction was carried out following the 
general procedure described above affording 0.146 
g of a brownish solid (94% yield). Mp 97.7 ºC with 
decomposition. IR, (ῡ/cm–1): 3420 (NH), 1580 (C=N), 
1552, 1505, 1488 (C=C aromatic). 1H NMR (200 MHz, 
DMSO-d6), δ/ppm: 12.67 (1 H, s, NH); 8.94 (1 H, d, 
H-quinoline); 8.69 e 8.64 (2 H, m, H-quinoline and 
CH=N); 8.08 (1 H, d, H-quinoline); 7.82-7.68 (5 H, m, 
H-quinoline and ArOCH3); 7,24 (1 H, s, H-thiazole); 
6.97 (2 H, d, ArOCH3); 3.78 (3 H, s, OCH3). 13C NMR 
(50 MHz, DMSO-d6), δ/ppm: 168.0 (SC=N); 159.3 
(C-ArOCH3); 150.9, 150.4, 148.5 (C-4 thiazole, 2 x 
C-quinoline); 138.2 (C-quinoline); 137.9 (CH=N); 130.1, 
130.0 (2 x C-quinoline); 127.8 (C-quinoline); 127.7 
(C-ArOCH3); 127.3 (C-quinoline); 124.7 (C-ArOCH3); 
126.6 (C-quinoline); 119.3 (C-quinoline); 114.4 
(C-ArOCH3); 102.7 (CH-thiazole); 55.5 (OCH3).
4-(4-Methoxyphenyl)-2-(2-((5-(4-nitrophenyl)furan-2-
yl)methylene)hydrazinyl)thiazole (2i). 
The reaction was carried out following the general 
procedure described above affording 0.080 g of a 
dark red solid (quantitative yield). Mp 202.9 ºC with 
decomposition. IR, (ῡ/cm–1): 3372 (NH), 1618 (C=N), 
1608, 1608, 1487 (C=C aromatic), 1509, 1331 (NO2). 1H 
NMR (200 MHz, DMSO-d6), δ/ppm: 8.26 (2 H, broad s., 
ArNO2); 7.99-7.96 (3 H, m, CH=N + ArNO2); 7.75 (2 H, 
broad s., ArOCH3); 7.42 (1 H, s, H-thiazole); 7.19 (1 H, s, 
H-4 furan); 6.99 (4 H, broad s., NH, H-3 furan, ArOCH3); 
3.78 (3 H, s, OCH3). 13C NMR (50 MHz, DMSO-d6), δ/
ppm: 167.7 (SC=N); 159.0 (C-ArOCH3); 151.8, 151.0, 
149.2 (C-4 thiazole, C-2 and C-5 furan); 146.1 (C-ArNO2); 
135.2 (C-ArNO2); 131.5 (CHC=N); 126.9 (C-ArOCH3); 
126.7 (C-ArOCH3); 124.5, 124.3 (C-ArNO2); 114.7 (C-4 




Jurkat (human T cells leukemia), HL-60 (human 
promyelocytic leukemia) and MCF-7 (breast carcinoma) 
cell lines were generously donated by Dr. Gustavo P. 
S. F. P. Braga, N. C. Fonseca, J. P. Ramos, E. M. Souza-Fagundes, R. B. Oliveira302
Amarante-Mendes of Universidade de São Paulo-USP 
and Professor Alfredo Goes (Universidade Federal de 
Minas Gerais). Vero cells (derived from the kidney of 
an African green monkey) were donated by Erna Kroon 
(Universidade Federal de Minas Gerais).
Leukemic cells were kept in a RPMI 1640 medium 
(Sigma Aldrich, USA) supplemented with 1% antibiotic 
solution (100 U/mL penicillin and 100 µg/mL streptomycin 
- GIBCO BRL, Grand Island, NY), buffered with 2 mM 
of L-glutamina (GIBCO UK, Grand Island, NY) 10% of 
fetal bovine serum (GIBCO BRL, Grand Island, NY), 
being incubated under a 5% CO2 atmosphere at 37 °C. 
MCF-7 cells were kept in D-MEM (Sigma Aldrich, USA), 
supplemented as described for leukemic cells but 5% of 
fetal bovine serum. All cultures were maintained at 37 ºC 
in a humidified incubator with 5% CO2 and 95% air. The 
media were changed twice weekly and they were regularly 
examined.
Cytotoxicity assays
The screening assays to evaluate the cytotoxic effects 
of the thiosemicarbazones and their thiazole derivatives 
were performed in 96 well plate using HL60 and Jurkat 
cells at 50,000 and 100,000 cells/well, respectively. 
MCF-7 and Vero cells were seeded at 10,000 cells/well. 
The plates were pre-incubated for 24 h at 37 ºC to allow 
adaptation of cells prior to the addition of the compounds 
at 50 µM. Treated and untreated cells (DMSO 0.5%) were 
incubated for 48 hours and compounds that inhibited the 
cell viability greater than 50% had the IC50 values obtained 
graphically from concentration-effect curves using Prism 
5.0 (GraphPad Software Inc.). Etoposide was used as 
positive control under the same experimental conditions. 
All substances were evaluated in two independent 
experiments, in triplicate. Cell viability was estimated by 
MTT assay.
In vitro cell viability assay - MTT assay
Viability assay was measured by MTT method 
(Mosmann, 1983). In brief, after 4 hours of the end of 
incubation of cells with different compounds, 20 μL of 
MTT solution (5mg/mL in phosphate-buffered saline) 
were added to each well, the supernatant was removed 
and 200 μL of 0.04 M HCl in isopropyl alcohol were 
added to solve the formazan crystal. Absorbance of the 
samples (treated and untreated) was measured at in a 
spectrophotometer at 570 nm. Data were expressed as 
perceptual of cell viability comparing with DMSO (0.5%). 
Values of absorbance of medium plus drugs, without cells 
were used to escape from false positive or false negative 
(Ulukaya, Colakogullari, Wood, 2004).
Determination of hypodiploid DNA content by using a 
hypotonic fluorochrome solution (HFS)
The proapoptotic potential of the most actives 
compounds was evaluated by quantifying of hypodiploid 
DNA content, as described by Nicoletti and coworkers 
(1991). The cells were treated with compounds (50 µM) 
and incubated for 24 hours. A total of 2.0 X 105 cells were 
resuspended in 0.3 ml of hypotonic fluorochrome solution 
(50 µg/mL propidium iodide and 0.1% Triton X-100 in 
0.1% sodium citrate). After 2–4 h at 4 °C in the dark, the 
fluorescence of individual nuclei was measured using 
a FACS flow cytometer (Becton–Dickinson, Mountain 
View, CA).
RESULTS AND DISCUSSION
The thiosemicarbazones (1a-f) and their cyclic 
derivatives (2a-i) were synthesized as shown in Figure 
2. Initially, the thiosemicarbazones were obtained using 
a classic methodology, by reacting an aromatic aldehyde 
with thiosemicarbazide. Then, the thiosemicarbazones 
were subjected to a cyclizat ion reaction in the 
presence of α-bromoacetophenone. Non-substituted 
α-bromoacetophenone (R2 = H) or para substituted by a 
methoxyl group (R2 = OCH3) were used for comparison 
purpose. The presence of a methoxyl group, besides 
improving compound solubility, could contribute as a 
possible hydrogen bond acceptor with the molecular 
target. 
All compounds were tested at 50 µM against three 
human cancer cell lines: HL60 (promyelocytic leukemia), 
Jurkat (acute lymphoblastic leukemia), and MCF-7 (breast 
cancer) (Table I). The drug etoposide was utilized at 
10 µM as positive control. 
Three compounds were able to inhibit more than 
50% of the growth of at least one of the cancer cell lines 
and then their IC50 values were determined. In addition, 
cytotoxicity of the active compounds was evaluated 
against African green monkey kidney epithelial cells 
(Vero cells), a model used to investigate possible 
toxicity against non-tumor cell lines (Küster et al., 2012) 
(Table II).
Results from the initial screening allowed us to select 
three compounds (2d, 2f, and 2h) able to inhibit more 
than 50% of viability of breast carcinoma cells (MCF-7) 
(IC50 values 54, 43, and 76 µM, respectively). Among the 
tested compounds, only the thiazole 2h exhibited activity 
against promyelocytic leukemia cells (HL-60) with an IC50 
value of 43 µM. None of the compounds tested showed 
significant cytotoxic activity against Jurkat cells. The 
concentration of the three compounds that inhibited Vero 
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cell proliferation by 50% (IC50) was greater than 100 µM, 
indicating low toxicity. 
Accordingly with the results obtained, we were able 
to conclude that the presence of a thiazole ring is essential 
for activity against MCF-7 cells, since corresponding 
thiosemicarbazones 1d and 1f, at the same concentration, 
were less active. Furthermore, in some cases, the presence 
of a second heterocyclic ring, quinoline (2d and 2h) 
or furan (2f), favored the cytotoxic activity. However, 
for the pyridine derivative 2e and furan derivative 2i, 
the presence of an additional heterocyclic ring did not 
result in a significant improvement in the activity. With 
respect to antiproliferative activity against HL-60 cells, 
comparison between 2d and 2h indicates the importance 
of the methoxyl group. 
The effect of anticancer drugs on tumor cell lines 
such as HL60 and MCF-7 has been associated with 
apoptosis induction (Robinson, Shewach, 2001). In order to 
identify the pro-apoptotic potential of the more promising 
compounds (2d, 2f and 2h), the hypodiploid DNA content, 
which permits the evaluation of DNA fragmentation of 
cells undergoing apoptosis, was determined. In this assay, 
propidium iodide intercalates into the base pairs of double-
stranded DNA, allowing the quantification of subdiploid 
DNA content and of the cells in different phases of the cell 
cycle (vide experimental section for details). The results 
summarized in Table II show that compound 2h induced 
a significant increase (90%) of subdiploid DNA content 
in HL-60 cells, similar to etoposide. Regarding the MCF-
7 cells, the three compounds tested induced an increase 
of approximately 50% in the hypodiploid DNA. These 
data suggest that the cytotoxic effect of these compounds 
is related to the activation of the apoptosis pathways. 
It is noteworthy that etoposide exhibits low activity 
(IC50 > 100 µM) against MCF-7 cells. 
The susceptibility of HL60 and MCF-7 to the 
thiazole compounds 2d, 2f, and 2h can be correlated 
with p53 status, a tumor suppressor that is responsible 
for triggering distinct responses to cellular stress and 
for mediating several of the antiproliferative processes, 
including apoptosis induction in response to DNA 
damage, among others (Fridman, Lowe, 2003). Cancer 
cells that express only mutated p53 protein have shown 
differential sensitivity to therapeutic modalities such as 
chemotherapeutic drugs or ionizing radiation, mediated 
by its inability to recognize DNA damage and promote 
damage repair or apoptosis (Robinson, Shewach, 2001; Ju 
et al., 1998). In the current investigation, the two lineages 
more susceptible to the new thiazole compounds possess 
different status of the p53 protein. HL60 (promyelocytic 
leukemia) lacks p53 (p53-null), which is very sensitive 
to various apopotic stimuli (Shimizu, Pommier, 1996), 
and MCF-7 (human breast carcinoma), a wild-type p53 
(Robinson, Shewach, 2001). The two strains showed 
differential behavior towards the treatments with the three 
promising compounds. Whereas HL60 was sensitive 
only to 2h, MCF-7 cells demonstrated more sensibility 
to the three compounds. Compound 2h induced DNA 
fragmentation in both lineages (p53-null and wild-type). 
Since the HL-60 cell line does not express p53, it may be 
concluded that apoptosis induced by 2h is not dependent 
on this pathway. Therefore, this thiosemicarbazone can 
trigger different mechanisms of cell death independent of 
p53, which needs to be further investigated. 
FIGURE 2 - Route of synthesis of the thiosemizarbazones and their corresponding thiazole heterocycles.
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Compounds 2d and 2f induced an increase of DNA 
subdiploid in MCF-7 cells, but not in HL60 (p53-null). It 
has been described that exposure of wild-type p53 cells to 
DNA-damaging agents increases p53 protein levels leading 
to G1 or G2 cell cycle blockage or apoptosis induction 
(Robinson, Shewach, 2001). The cross-talking between 
p53 function and cytotoxicity is a complex process and 
dependent upon the particular cytotoxic agent, cell line, and 
TABLE I - Cytotoxicity activity assay results of synthesized compounds against tumor cells
 
Compounds R1 R2
% inhibition of cell proliferation
HL60 Jurkat MCF-7
1a Ph - 5.9 ± 3.7 0 8.5 ± 3.5
1b 
 
- 23.3 ± 6.0 16.0 ± 4.3 2.6 ± 3.5
1c  - 11.6 ± 5.0 6.2 ± 2.1 24.7 ± 0.4
1d 
 
- 0 38.2 ± 10.5 28.9 ± 6.1
1e  - 0 0 10.9 ± 4.5
1f 
 
- 7.5 ± 1.0 37.6 ± 6.5 11.0 ± 7.0
2a Ph H 9.2 ± 0.3 2.9 ± 2.3 19.3 ± 5.4
2b 
 
H 0 15.4 ± 7.9 33.5 ± 3.6
2c  H 16.9 ± 4.2 0 4.3 ± 0.6
2d 
 
H 45.7 ± 1.6 32.6 ± 15.6 56.1 ± 0.1
2e  H 26.0 ± 2.1 6.0 ± 4.9 44.9 ± 4.7
2f 
 
H 26.6 ± 1.2 42.3 ± 13.2 50.6 ± 4.2
2g 
 
OCH3 33.6 ± 11.9 43.3 ± 1.1 39.6 ± 8.1
2h 
 
OCH3 82.2 ± 4.8 34.5 ± 12.1 58.7 ± 3.3
2i 
 
OCH3 37.7 ± 2.4 18.1 ± 16.9 13.8 ± 1.0
Etoposide - - 68.7 ± 11 54 ± 10 inactive
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cell death pathways used. Our results also corroborated the 
data by (Tudor et al., 2000), that demonstrated differences 
in susceptibility to drugs in HL60 and MCF-7 which 
has been attributed to qualitative changes in apoptotic 
protein expression, after exposure to agents with different 
mechanisms of action. Under our conditions, the positive 
control etoposide, used in the clinic, induced DNA 
fragmentation in HL60, but not in MCF-7. Shimizu and 
Pommier (1996) reported that topoisomerase inhibitors 
such as etoposide induce massive apoptosis in HL60 cells 
with the typical internucleosomal DNA fragmentation. 
Resistance to drugs, specifically to etoposide as observed 
in MCF-7, may arise as a result of alterations in target 
expression and activity, increased drug efflux, and alterations 
in DNA damage response mechanisms (Aktan et al., 2014). 
Therefore, further experiments should be conducted 
to elucidate the mechanism/s involved in the cytotoxic 
effect of the new thiosemicarbazones on these cell lines.
CONCLUSION
A series of thiosemicarbazones and their thiazole 
derivatives were synthesized in this work. All compounds 
were evaluated in vitro against three human cancer cell lines. 
Among the tested compounds, the thiazole heterocycles 2d, 
2f and 2h exhibited moderate cytotoxicity activity against 
HL60 and/or MCF-7 cell lines (IC50 range: 43-76 M) 
and low cytotoxicity against Vero cells (normal cells) 
(IC50 > 100 µM). The potential pro-apoptotic of the three 
compounds was investigated, demonstrating a difference in 
induction of DNA fragmentation in HL60 and MCF-7 cells. 
Among the active compounds, 2h displayed the best results 
in this preliminary study and can be considered a promising 
lead compound in the design of more potent analogues.
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